BRAF and melanoma: A literature search of the remaining BRAF variant-mutant including BRAF G469A, D594E, D594N, D594H in vulvovaginal melanomas revealed possible inactivating mutations that were less likely to respond to vemurafenib, which is the FDA-approved selective inhibitor of the V600E mutant BRAF kinase used to treat patients who have metastatic or unresectable melanoma with BRAF mutations [27].